Starte jetzt beim Kostensieger der Stiftung Warentest (12/2025)

Bei unserem Broker finanzen.net ZERO handelst du alle deine Aktien ohne Ordergebühren (zzgl. Spreads). Wechsle jetzt und spare bei jedem Trade!

Nicht mehr anzeigen

Aurinia Pharmaceuticals Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

12,38 EUR -0,01 EUR -0,04 %

16:32:02

STU

14,60 USD ±0,00 USD ±0,00 %

16:46:26

BTT

Aurinia Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.1,66 Mrd. EUR

KGV228,50Div. Rendite0,00%

WKNA1W7D4

ISINCA05156V1022

SymbolAUPH

Aurinia Pharmaceuticals Aktien News

Sortieren:Datum Meistgelesen

20.07.23BusinesswireAurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023

29.06.23BusinesswireAurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

20.06.23BusinesswireAurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

01.06.23BusinesswireLUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone

26.05.23BusinesswireAurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

17.05.23BusinesswireAurinia Announces 2023 Annual General Meeting Results

09.05.23BusinesswireAurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

04.05.23BusinesswireAurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

02.05.23BusinesswireISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual General Meeting

02.05.23BusinesswireAurinia Pharmaceuticals Announces Swissmedic Approval of LUPKYNIS® (voclosporin)

28.04.23BusinesswireGlass Lewis Recommends Aurinia Shareholders Vote "FOR” ALL Company Director Nominees at 2023 Annual Meeting

25.04.23BusinesswireToni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys

24.04.23BusinesswireAurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023

11.04.23BusinesswireAurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

05.04.23BusinesswireAurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

03.04.23BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06.03.23BusinesswireAurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

28.02.23BusinesswireAurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company Updates

Aurinia Pharmaceuticals News

Aurinia Pharmaceuticals News: auf dieser Seite finden Sie alle Aurinia Pharmaceuticals News und Nachrichten zur Aurinia Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Aurinia Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Aurinia Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.